

In case of emergency, or if you find this card, please contact the healthcare provider listed below.

Erdafitinib's prescriber name:

.....

Prescriber's clinic, center, or hospital name:

.....

Prescribers' telephone number:

.....



Information Card for Erdafitinib-Treated Patients

IMPORTANT MEDICAL INFORMATION INSIDE

Erdafitinib patients: Please carry this card, and provide it to your eye care specialist or healthcare provider at every appointment. The intent of this card is to alert your eye specialist or healthcare provider that you are receiving BALVERSA™ treatment, and of the necessary eye exams you require. For further information, please refer to the Patient Information that is provided with your treatment.

Patient's name:

I am taking the following medication: **Erdafitinib**

Dear Healthcare Professional,

Eye problems are common when taking erdafitinib and can include dry or inflamed eyes, inflamed cornea (front part of the eye), and disorders of the retina including central serous retinopathy (**CSR**).¹

CSR symptoms with erdafitinib treatment include blurred vision, vision loss, or any other visual changes. Patients may display no symptoms, especially if the affected areas fall outside the macula.²

Erdafitinib-treated patients should receive monthly eye exams during the first 4 months of treatment and every 3 months afterwards, plus at any time if experiencing vision problems.

These examination should include: Optical coherence tomography, visual acuity, slit lamp examination, and fundoscopy.¹ **If CSR is detected, please contact the prescriber of erdafitinib named on the other side of this document.**

1. Balversa™ Prescribing Information. April 2020.

2. American Society of Retina Specialists. Central serous chorioretinopathy. <https://www.asrs.org/patients/retinal-diseases/21/central-serous-chorioretinopathy>

- If you have any additional questions, please contact Janssen Medical Information
 - RA-MedInfoEmMarkets@ITS.JNJ.com
- **Adverse events reporting guidance:**
 - SFDA (National Pharmacovigilance center)
 - Email: npc.drug@sfd.gov.sa
 - Telephone: 19999
 - Fax: +966 11 2057662
 - Online: <http://ade.sfda.gov.sa>
- For full prescribing information, please refer to the data sheet or contact **Johnson & Johnson Middle East FZ-LLC (Riyadh)**
 - Address: Prince Muhammed Bin Abdulaziz Rd, Tower B, Level 30 , Olaya towers.
 - Office Tel 00966-11- 4339133
 - Postal address: P O Box 65305 Riyadh 11556, Saudi Arabia
- To report Adverse Events/Product Complaint or any Medical Information Inquiries, please contact us at Email: GCC-PV2@its.jnj.com
 - Hotline: 00966540015811